The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Abstract
Purpose: We report two clinical trials in non–small cell lung cancer (NSCLC) patients evaluating immune response, toxicity, and clinical outcome after vaccination with the telomerase peptide GV1001: a phase II trial (CTN-2006) in patients vaccinated after chemoradiotherapy and an 8-year update on a previously reported phase I/II trial (CTN-2000). Experimental Design: CTN-2006: 23 inoperable stage III patients received radiotherapy (2 Gy × 30) and weekly docetaxel (20 mg/m2), followed by GV1001 vaccination. CTN-2000: 26 patients were vaccinated with two telomerase peptides (GV1001 and I540). The immune responses were evaluated by T-cell proliferation and cytokine assays. Results: CTN-2006 trial: a GV1001-specific immune response developed in 16/20 evaluable patients. Long-term immunomonitoring showed persisting responses in 13 subjects. Serious adverse events were not observed. Immune responders recorded a median PFS of 371 days, compared with 182 days for nonresponders (P = 0.20). CTN-2000 trial update: 13/24 evaluable subjects developed a GV1001 response. The immune responders achieved increased survival compared with nonresponders (median 19 months vs. 3.5 months; P < 0.001). Follow-up of four long-time survivors showed that they all harbored durable GV1001-specific T-cell memory responses and IFNγhigh/IL-10low/IL-4low cytokine profiles. Two patients are free of disease after 108 and 93 months, respectively. Conclusions: Vaccination with GV1001 is well tolerated, immunizes the majority of NSCLC patients and establishes durable T-cell memory. The considerable immune response rate and low toxicity in the phase II trial support the concept of combining chemoradiotherapy with vaccination. The survival advantage observed for immune responders warrants a randomized trial. Clin Cancer Res; 17(21); 6847–57. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 1×
“The enzyme telomerase is expressed in most human cancers, including NSCLC (7, 8) and is considered as an attractive target for a universal cancer vaccine (9-14).”
BackgroundIdentification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“Tumor cells bypass this biological clock by expressing telomerase, that synthesises new telomereunits (9, 16).”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · cited 1×
“combinatory regimes, but sparse data from clinical studies on how the different modalities interact (24, 26, 39).”
BackgroundSu, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359 · cited 1×
“The enzyme telomerase is expressed in most human cancers, including NSCLC (7, 8) and is considered as an attractive target for a universal cancer vaccine (9-14).”
BackgroundGjertsen, M. K., Buanes, T., Rosseland, A. R., Bakka, A., Gladhaug, I., S�reide, O., Eriksen, J. A., M�ller, M., Baksaas, I., Lothe, R. A., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1205 · Cited by 276 · cited 1×
“Thawed PBMCs were stimulated once in vitro with the vaccine peptide prior to Tcell assays, as described earlier (6, 20, 37).”
MethodSelf-citation
Cited by
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Self-citationPeptide Vaccine: Progress and Challenges
Li, W., Joshi, M., Singhania, S., Ramsey, K., & Murthy, A. (2014) · Vaccines · doi:10.3390/vaccines2030515 · Cited by 679
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer
Ko, E. C., Raben, D., & Formenti, S. C. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3620 · Cited by 278
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Metadata
- Authors
- Brunsvig, P. F., Kyte, J. A., Kersten, C., Sundstrøm, S., Møller, M., Nyakas, M., Hansen, G. L., Gaudernack, G., & Aamdal, S.
- Venue
- Clinical Cancer Research
- Published
- 2011-10-31
- Volume
- 17
- Issue
- 21
- Pages
- 6847-6857
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2123291375
- Cited by
- 159
- References
- 7
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1385
- The paper
- Brunsvig, P. F., Kyte, J. A., Kersten, C., Sundstrøm, S., Møller, M., Nyakas, M., Hansen, G. L., Gaudernack, G., & Aamdal, S. (2011). Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1385
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.